EPCAM and breast cancer: Key findings include the enrichment of immunosuppressive CXCR2+ TANs and reduced vascular components in PDAC, diverse CAF subsets with distinct signaling roles in ESCC and BC, unique plasma-cell features in GC, and organ-specific stromal adaptations such as low EPCAM expression in HCC and preserved tumor suppressor and/or mesenchymal genes in TC.